Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);

clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.

Learn more about the EU Clinical Trials Register including the source of the information and the legal basis.

The EU Clinical Trials Register currently displays 42118 clinical trials with a EudraCT protocol, of which 6925 are clinical trials conducted with subjects less than 18 years old.
The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02 Art. 3 par. 2 and Commission Guideline 2012/C 302/03, Art. 5) .

Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (42,032)
Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)

42,032 result(s) found. Displaying page 1,786 of 2,102.

EudraCT Number: 2021-000192-37

Sponsor Protocol Number: 2019_0007

Start Date*: 2021-10-04

Sponsor Name:Hôpital Foch

Full Title: Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide

Medical condition: Patients with a diagnosis of Glioblastoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018337	Glioblastoma multiforme	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018336	Glioblastoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-000824-21

Sponsor Protocol Number: IJB-NERABRAIN-ODN-007

Start Date*: 2021-10-05

Sponsor Name:Institut Jules Bordet

Full Title: An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancer

Medical condition: HER2 positive breast cancer patients with brain metastases

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10027475	Metastatic breast cancer	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: FR (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2021-001965-19

Sponsor Protocol Number: RC21_0144

Start Date*: 2021-11-05

Sponsor Name:chu de NANTES

Full Title:

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10007541 - Cardiac disorders	10007541	Cardiac disorders	SOC
	20.0	10047065 - Vascular disorders	10021097	Hypotension	PT

Population Age: Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-000086-17

Sponsor Protocol Number: AK901

Start Date*: 2020-08-06

Sponsor Name:Akari Therapeutics Plc

Full Title: Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10005329 - Blood and lymphatic system disorders	10043645	Thrombotic microangiopathy	PT
	21.1	10042613 - Surgical and medical procedures	10063581	Stem cell transplant	PT
	22.0	10042613 - Surgical and medical procedures	10067859	Allogenic stem cell transplantation	PT
	22.0	10042613 - Surgical and medical procedures	10081347	Autologous haematopoietic stem cell transplant	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2004-001241-14	Sponsor Protocol Number: V00096 CR 201	Start Date*: 2004-11-12
Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
Full Title: Efficacy of topic RV3131A-HC3221 in the prevention of polymorphic light eruption
Medical condition: Polymorphic Light Eruption (PMLE)
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: AT (Completed) DE (Completed) GB (Completed) SE (Completed)
Trial results: View results

EudraCT Number: 2021-001575-16

Sponsor Protocol Number: 2017-02-32-005

Start Date*: 2021-11-29

Sponsor Name:Centre Régional de lutte contre le Cancer Eugène Marquis

Full Title: A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine ...

Medical condition: Patients having operable intrahepatic cholangiocarcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10073077	Intrahepatic cholangiocarcinoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2004-001546-32	Sponsor Protocol Number: CLAF237A2305	Start Date*: 2004-09-07
Sponsor Name:Novartis Finland Oy
Full Title: A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with ...
Medical condition: Patients with type 2 diabetes
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed) LT (Completed) SE (Completed)
Trial results: View results

EudraCT Number: 2005-004597-24

Sponsor Protocol Number: 1218.6

Start Date*: 2006-03-29

Sponsor Name:Boehringer Ingelheim Limited

Full Title: A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as ad...

Medical condition: Patients with type 2 diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10012613	Diabetes mellitus non-insulin-dependent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed) SE (Completed) SK (Completed)

Trial results: View results

EudraCT Number: 2004-004255-18	Sponsor Protocol Number: CSPP100A2324	Start Date*: 2005-03-30
Sponsor Name:Novartis Pharma Services AG
Full Title: An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients ≥ 65 years of age with essential hyperten...
Medical condition: Hypertension
Disease:
Population Age: Elderly		Gender: Male, Female
Trial protocol: SE (Completed) AT (Completed) IT (Completed)
Trial results: View results

EudraCT Number: 2005-002778-30	Sponsor Protocol Number: CLAF237A2357	Start Date*: 2005-10-19
Sponsor Name:Novartis Pharma Services AG
Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaire...
Medical condition: Type II Diabetes
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Completed) DE (Completed) FI (Completed) SE (Completed) ES (Completed)
Trial results: View results

EudraCT Number: 2004-001500-13

Sponsor Protocol Number: A0081012

Start Date*: 2005-01-24

Sponsor Name:Pfizer Ltd.

Full Title: An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...

Medical condition: Generalized Anxiety Disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	7.0		10018105		LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: IE (Completed) SE (Completed) GB (Completed) ES (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2004-001186-17

Sponsor Protocol Number: CE1145_3001

Start Date*: 2005-09-05

Sponsor Name:ZLB Behring GmbH

Full Title: Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks

Medical condition: Hereditary angioedema (HAE) is characterized by congenital C1-INH deficiency. This is reflected by insufficient plasma concentrations of C1 – inhibitor or by synthesis of dysfunctional C1 – inhibit...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	7.0		10019860		LLT

Population Age: Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) GB (Completed) ES (Completed) CZ (Completed) SE (Completed) BG (Completed)

Trial results: View results

EudraCT Number: 2006-004608-37

Sponsor Protocol Number: FER-CARS-02

Start Date*: 2007-07-27

Sponsor Name:Vifor Pharma, Vifor (International) Ltd.

Full Title: A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iro...

Medical condition: iron deficiency in patients with chronic heart failure

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10022970	Iron deficiency	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Completed) IT (Completed) CZ (Completed) GR (Completed) SE (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2008-001640-40

Sponsor Protocol Number: 1218.46

Start Date*: 2008-11-20

Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG

Full Title: A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin ...

Medical condition: Patients with type 2 diabetes • with insufficient glycaemic control (HbA1c ≥ 7.5 to < 11 % at Visit 2) • with very poor glycaemic control (HbA1c ≥ 11 %)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed) DE (Completed) FR (Completed) SE (Completed) EE (Completed) LT (Completed)

Trial results: View results

EudraCT Number: 2004-000299-15	Sponsor Protocol Number: BC1-03	Start Date*: 2004-11-03
Sponsor Name:Algeta AS
Full Title: A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
Medical condition: The target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer.
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: SE (Completed) GB (Completed)
Trial results: View results

EudraCT Number: 2004-000483-27	Sponsor Protocol Number: PRA/BIA-2093-302	Start Date*: 2004-08-19
Sponsor Name:BIAL - Portela & Ca, S.A.
Full Title: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.
Medical condition: Refractory partial epilepsy
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Completed) ES (Completed) DK (Completed)
Trial results: View results

EudraCT Number: 2007-004585-40

Sponsor Protocol Number: 1218.20

Start Date*: 2008-01-25

Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG

Full Title: A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two ye...

Medical condition: Patients with type 2 diabetes.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) IE (Completed) FR (Completed) SE (Completed) NL (Completed) GB (Completed) DK (Completed) HU (Completed) IT (Completed) BG (Completed)

Trial results: View results

EudraCT Number: 2007-003224-38

Sponsor Protocol Number: D4320C00015

Start Date*: 2007-12-07

Sponsor Name:AstraZeneca AB

Full Title: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer ...

Medical condition: Hormone-refractory prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10062904	Hormone-refractory prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) SE (Completed) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) LV (Completed) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2007-007834-21

Sponsor Protocol Number:

Start Date*: 2008-04-07

Sponsor Name:Odense University Hospital

Full Title: FLOX + Erbitux. 1. line treatment to patients with metastatic colorectal cancer and wild type K-RAS tumor. A phase II study.

Medical condition: Patients with metastatic colorectal cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10061451	Colorectal cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed) SE (Completed)

Trial results: View results

EudraCT Number: 2008-000750-13	Sponsor Protocol Number: 1218.40	Start Date*: 2008-06-30
Sponsor Name:Boehringer Ingelheim Finland Ky
Full Title: A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.
Medical condition: Patients with type 2 Diabetes Mellitus.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed) NL (Completed) SE (Completed) AT (Completed) SK (Completed) DE (Completed) ES (Completed) GB (Completed) CZ (Completed) BE (Completed) HU (Completed) IT (Completed) GR (Completed) PT (Prematurely Ended)
Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.

The status of studies in GB is no longer updated from 1.1.2021
For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands Legal notice

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA